JP5070549B2 - 腫瘍選択的蛍光染色剤 - Google Patents
腫瘍選択的蛍光染色剤 Download PDFInfo
- Publication number
- JP5070549B2 JP5070549B2 JP2008502780A JP2008502780A JP5070549B2 JP 5070549 B2 JP5070549 B2 JP 5070549B2 JP 2008502780 A JP2008502780 A JP 2008502780A JP 2008502780 A JP2008502780 A JP 2008502780A JP 5070549 B2 JP5070549 B2 JP 5070549B2
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- group
- fluorescein
- tumor
- fluorescent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 50
- 239000007850 fluorescent dye Substances 0.000 title description 26
- 201000011510 cancer Diseases 0.000 claims description 25
- 150000001875 compounds Chemical class 0.000 claims description 25
- 239000002872 contrast media Substances 0.000 claims description 17
- 238000003745 diagnosis Methods 0.000 claims description 15
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 6
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 6
- 201000004101 esophageal cancer Diseases 0.000 claims description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 206010061825 Duodenal neoplasm Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010054184 Small intestine carcinoma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 201000000312 duodenum cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 29
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical class O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 24
- 210000004881 tumor cell Anatomy 0.000 description 21
- CHADEQDQBURGHL-UHFFFAOYSA-N (6'-acetyloxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 CHADEQDQBURGHL-UHFFFAOYSA-N 0.000 description 19
- 230000005284 excitation Effects 0.000 description 17
- 238000000034 method Methods 0.000 description 15
- -1 fluorescein ester Chemical class 0.000 description 12
- 108090000371 Esterases Proteins 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 241000700159 Rattus Species 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 239000000032 diagnostic agent Substances 0.000 description 7
- 229940039227 diagnostic agent Drugs 0.000 description 7
- 230000001678 irradiating effect Effects 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 6
- 210000002429 large intestine Anatomy 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 5
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 4
- 101100468538 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RGM1 gene Proteins 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000003238 esophagus Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000012327 Endoscopic diagnosis Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical class [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 2
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- SJLBIPLIGYWGJV-UHFFFAOYSA-N N-nitroso-N-methyl-4-aminobutyric acid Chemical compound O=NN(C)CCCC(O)=O SJLBIPLIGYWGJV-UHFFFAOYSA-N 0.000 description 2
- 229960002749 aminolevulinic acid Drugs 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Description
Proc. Natl. Acad. Sci. USA, 55, 134-141, 1966 The Journal of Histochemistry and Cytochemistry, 29, pp.503-510, 1981
さらに、上記の診断薬、上記の造影剤、及び上記の診断方法において、上記一般式(I)で表される化合物とともに、又は上記一般式(I)で表される化合物に替えて、シアニン系化合物を用いてもよく、このような診断薬、造影剤、及び診断方法も本発明により提供される。
例1:候補化合物の選出
培養細胞系にて候補化合物の選別をおこなった。培養細胞としては、ラット正常胃粘膜上皮由来細胞RGM1、及びそのトランスフォーム細胞であるRGK1を正常細胞及びがん細胞のモデル細胞として使用した。RGM1及び RGK1の培養にはDMEM/HAM F12=1:1培地(10%FBS, 0.1% penicillin streptomycinを用いた。それぞれの細胞に下記に示した化合物(濃度0.1M)を10分間ロードした後、培地を化合物非含有培地に交換し、一定時間後にFlow Cytometryから平均蛍光強度を求めた。各化合物の有効性はRGM1に対するRGK1の平均蛍光強度比により評価した。この結果、フルオレセインのエステル誘導体であるFDA(フルオレセインジアセテート)の蛍光強度比が最も高くなり、またその強度比は時間に依存して変化することが明らかとなった(図1)。
FDAはエステラーゼ感受性蛍光プローブであり、拡散で細胞に入った後に細胞内のエステラーゼで加水分解されて蛍光性のフルオレセインを生成し、徐々に細胞外へと漏出する。フルオレセインの細胞外漏出はフルオレセインがFDAに比べて親水性であることからFDAの細胞内取り込みに比べて非常にゆっくりと起きる。この過程を正常細胞及びがん細胞で比較した。2種類の細胞溶解液の加水分解酵素活性を比較したところ、RGK1がFDAに対して約2倍高い加水分解活性を有していた。また、フルオレセインの漏出速度を比較すると、RGM1に比べてRGK1の方が遅いことが分かった。これらの結果から、がん細胞における高い加水分解酵素活性と低い漏出速度の2つの要因によって、FDAでは正常細胞に対してがん細胞において高い蛍光強度比を与えたものと考えられた。
FDAのアセチルエステルを各種のエステルに変換した下記表1の各誘導体について例1と同様にしてフローサイトメトリーにより比較した結果を図2に示す。その結果、フルオレセインジアクリレート(FDAcr)が正常細胞とがん細胞との識別性能に極めて優れていることが明らかになった。
FDAcrを用いて蛍光顕微鏡下でのイメージングを行った。蛍光顕微鏡下(オリンパス社製IX71、励起波長470-490 nm、フィルター500 nm)で観察したところ、例3の結果と同様に、がん細胞において強い蛍光が認められ、がん細胞と正常細胞とを明確に区別できることが確認された。
FDAcrを用いて食道癌モデルであるNMBAラットのイメージングを行なった。ラット(オス、10週齢)にNMBA 1 mgを皮下注射し、第1〜5週は週5回投与し、第6〜15週は週1回投与し、第16週以降に実験に使用した。ラットをネンブタール腹腔内投与(1 mL/kg体重)により麻酔し、仰向けにして台に固定して気道を確保した。内視鏡を食道に挿入して観察を行った。実験系を図3に示し、結果を図4に示す。食道癌病変部の蛍光強度が周囲の正常組織に比べて高いことが観察された。この結果から、内視鏡下でFDAcrを用いることにより癌病変部と正常組織を区別できることが示された。
例5と同様にしてシアニン系の近赤外蛍光色素であるCy-7を用いて蛍光内視鏡像を得た。Cy-7では非病変部と思われる部分からも蛍光が観察されたが、主として食道内に突出している瘤状の病変部からCy-7由来の蛍光が観察され、病変部が蛍光染色されていることが示された。
FDAcrを用いて大腸癌モデルラットのイメージングを行なった。大腸癌モデルラットをエーテル麻酔し、大腸内を0.6%酢酸水溶液で洗浄した。37℃に保ったPBSで大腸内を2〜3回洗浄し、100μM FDAcr(PBS溶液)15 mlを肛門より注腸し、肛門を塞いで3分間静置した。3分後に37℃に保ったPBSで2〜3回大腸内を洗浄した。大腸内にファイバースコープ(BF-3C40)を挿入して病変部を観察した。糞が観察の邪魔になる場合には適宜大腸内を洗浄した。結果を図5に示す。大腸癌部位(左側面、右下面)に強い蛍光が認められ、容易に癌診断が可能であった。
Claims (4)
- 内視鏡を用いた固形がんの診断に用いるための造影剤であって、下記の一般式(I):
- R1及びR2が-CH=CH2である請求項1に記載の造影剤。
- 胃癌、食道癌、十二指腸癌、気管支癌、肺癌、又は大腸癌の診断に用いるための請求項1又は2に記載の造影剤。
- 食道癌又は大腸癌の診断に用いるための請求項1又は2に記載の造影剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008502780A JP5070549B2 (ja) | 2006-02-28 | 2007-02-27 | 腫瘍選択的蛍光染色剤 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006051533 | 2006-02-28 | ||
JP2006051533 | 2006-02-28 | ||
JP2008502780A JP5070549B2 (ja) | 2006-02-28 | 2007-02-27 | 腫瘍選択的蛍光染色剤 |
PCT/JP2007/053566 WO2007099924A1 (ja) | 2006-02-28 | 2007-02-27 | 腫瘍選択的蛍光染色剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2007099924A1 JPWO2007099924A1 (ja) | 2009-07-16 |
JP5070549B2 true JP5070549B2 (ja) | 2012-11-14 |
Family
ID=38459030
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008502780A Active JP5070549B2 (ja) | 2006-02-28 | 2007-02-27 | 腫瘍選択的蛍光染色剤 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20080014147A1 (ja) |
EP (1) | EP1990063A4 (ja) |
JP (1) | JP5070549B2 (ja) |
CN (1) | CN101389357B (ja) |
WO (1) | WO2007099924A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080014147A1 (en) * | 2006-02-28 | 2008-01-17 | The University Of Tokyo | Tumor specific fluorescent dye |
JP5124780B2 (ja) * | 2006-03-03 | 2013-01-23 | 国立大学法人 東京大学 | 蛍光プローブ |
JP6165065B2 (ja) * | 2012-02-17 | 2017-07-19 | 国立大学法人 東京大学 | 蛍光プローブ |
WO2015174460A1 (ja) * | 2014-05-14 | 2015-11-19 | 国立大学法人 東京大学 | 酵素特異的な細胞内滞留性蛍光化合物 |
EP3493855A4 (en) | 2016-08-02 | 2020-04-01 | ISI Life Sciences, Inc. | METHOD FOR DETECTION OF CANCER CELLS. |
US10753942B2 (en) | 2017-05-15 | 2020-08-25 | Indicator Systems International, Inc. | Methods to detect remnant cancer cells |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5986271A (en) * | 1997-07-03 | 1999-11-16 | Lazarev; Victor | Fluorescence imaging system |
AU5209199A (en) * | 1998-07-08 | 2000-02-01 | Regents Of The University Of California, The | Use of fluorescent reagents in identification of cancerous cells and activated lymphocytes |
JP2005220045A (ja) * | 2004-02-04 | 2005-08-18 | Konica Minolta Medical & Graphic Inc | 蛍光造影剤 |
US20080014147A1 (en) * | 2006-02-28 | 2008-01-17 | The University Of Tokyo | Tumor specific fluorescent dye |
-
2007
- 2007-02-23 US US11/709,808 patent/US20080014147A1/en not_active Abandoned
- 2007-02-27 WO PCT/JP2007/053566 patent/WO2007099924A1/ja active Application Filing
- 2007-02-27 JP JP2008502780A patent/JP5070549B2/ja active Active
- 2007-02-27 CN CN2007800068360A patent/CN101389357B/zh not_active Expired - Fee Related
- 2007-02-27 EP EP07714959A patent/EP1990063A4/en not_active Withdrawn
-
2011
- 2011-02-01 US US13/018,831 patent/US20110165085A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2007099924A1 (ja) | 2007-09-07 |
US20110165085A1 (en) | 2011-07-07 |
JPWO2007099924A1 (ja) | 2009-07-16 |
EP1990063A1 (en) | 2008-11-12 |
US20080014147A1 (en) | 2008-01-17 |
EP1990063A4 (en) | 2011-06-08 |
CN101389357A (zh) | 2009-03-18 |
CN101389357B (zh) | 2011-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6006271B2 (ja) | 蛍光リン脂質エーテル化合物、組成物、及びその使用 | |
JP5070549B2 (ja) | 腫瘍選択的蛍光染色剤 | |
CN110167954B (zh) | 包含偶联至pH触发的多肽的荧光团的荧光化合物 | |
DK1937676T3 (en) | Biocompatible fluorescent imaging compounds | |
CN111362971B (zh) | 靶向psma的双苯并噻二唑类化合物及其制备方法与应用 | |
US20200390909A1 (en) | Drug fragment imaging agent conjugates | |
JP5425181B2 (ja) | 蛍光mriプローブ | |
GB2433117A (en) | Histology staining agent for use in endoscopy | |
EP2618849B1 (en) | Multivalent fluorescent probes | |
JP5476613B2 (ja) | 尿路上皮がんの検出方法 | |
US9409923B2 (en) | Drug-fluorophore complex for specific detection of tumor cells | |
WO2021229188A1 (fr) | Nouveaux composés fluorescents pour le marquage de tissu tumoral | |
JP4953761B2 (ja) | 内視鏡用組織染色剤組成物 | |
WO2022202863A1 (ja) | がん造影用組成物 | |
JP2008069107A (ja) | 内視鏡用組織蛍光染色剤 | |
JP2005170812A (ja) | 蛍光造影剤及び蛍光造影方法 | |
EP4196173A1 (en) | Compounds and compositions for tumor detection and surgical guidance | |
JP2005145819A (ja) | 蛍光造影剤および体外蛍光造影方法 | |
Monkemuller et al. | Learning curve of double-balloon enteroscopy (DBE) | |
JP2005145921A (ja) | 診断用蛍光造影剤及び蛍光造影診断方法 | |
Anagnostopoulos et al. | Endoscopic diagnosis of autoimmune gastritis is feasible with high resolution magnification endoscopy | |
Shonde et al. | Fibered confocal endomicroscopy: a feasibility study to enhance routine endoscopy | |
Muguruma et al. | Endoscopic Molecular Imaging in Gastrointestinal Oncology | |
Van Dam | Improving colorectal cancer screening: fact and fantasy | |
Kim et al. | The Efficacy of Chromoendoscopy with Indigocarmine in Detection of Ascending Colon and Cecum Lesions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100203 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120501 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120628 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120724 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |